Your browser doesn't support javascript.
loading
TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma.
Nakayama, Kazuhide; Szewczyk, Magdalena M; Dela Sena, Carlo; Wu, Hong; Dong, Aiping; Zeng, Hong; Li, Fengling; de Freitas, Renato Ferreira; Eram, Mohammad S; Schapira, Matthieu; Baba, Yuji; Kunitomo, Mihoko; Cary, Douglas R; Tawada, Michiko; Ohashi, Akihiro; Imaeda, Yasuhiro; Saikatendu, Kumar Singh; Grimshaw, Charles E; Vedadi, Masoud; Arrowsmith, Cheryl H; Barsyte-Lovejoy, Dalia; Kiba, Atsushi; Tomita, Daisuke; Brown, Peter J.
Afiliação
  • Nakayama K; Oncology Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
  • Szewczyk MM; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Dela Sena C; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Wu H; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Dong A; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Zeng H; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Li F; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • de Freitas RF; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Eram MS; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Schapira M; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Baba Y; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
  • Kunitomo M; Oncology Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
  • Cary DR; Oncology Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
  • Tawada M; Oncology Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
  • Ohashi A; Medicinal Chemistry Research Laboratory, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
  • Imaeda Y; Oncology Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
  • Saikatendu KS; Oncology Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
  • Grimshaw CE; Structiural Biology, Takeda California Inc., 10410 Science Center Drive, San Diego, CA 92121, USA.
  • Vedadi M; Enzymology and Biophysical Chemistry, Takeda California Inc., 10410 Science Center Drive, San Diego, CA 92121, USA.
  • Arrowsmith CH; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Barsyte-Lovejoy D; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
  • Kiba A; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
  • Tomita D; Princess Margaret Cancer Centre and Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 2M9, Canada.
  • Brown PJ; Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Oncotarget ; 9(26): 18480-18493, 2018 Apr 06.
Article em En | MEDLINE | ID: mdl-29719619

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Japão